Literature DB >> 11758077

Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin.

P B Ward1, P D Johnson, E A Grabsch, B C Mayall, M L Grayson.   

Abstract

We report the first instance in Australia of treatment failure due to a strain of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin--heteroresistant vancomycin-intermediate S. aureus (hVISA). The infection occurred in a 41-year-old man with multiple risk factors. No transmission of the organism to other patients or the environment was detected. This case may herald the beginning of a new phase of staphylococcal resistance in Australia.

Entities:  

Mesh：

Year:  2001        PMID： 11758077     DOI： 10.5694/j.1326-5377.2001.tb143681.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN： 0025-729X            Impact factor:   7.738


  17 in total

1.  Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

Authors:  Sebastian J van Hal; Michael C Wehrhahn; Thelma Barbagiannakos; Joanne Mercer; Dehua Chen; David L Paterson; Iain B Gosbell
Journal:  J Clin Microbiol       Date:  2011-01-26       Impact factor: 5.948

Review 2.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

3.  Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus.

Authors:  Mandy Wootton; T R Walsh; A P MacGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Laboratory detection and investigation of reduced susceptibility to vancomycin in oxacillin-resistant Staphylococcus aureus.

Authors:  P D Midolo; T M Korman; D Kotsanas; P Russo; T G Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-05       Impact factor: 3.267

5.  Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.

Authors:  Sarah W Satola; Monica M Farley; Karen F Anderson; Jean B Patel
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

6.  Mechanism of reduced vancomycin susceptibility conferred by walK mutation in community-acquired methicillin-resistant Staphylococcus aureus strain MW2.

Authors:  Jinfeng Hu; Xu Zhang; Xiaoyu Liu; Chuan Chen; Baolin Sun
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

7.  First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.

Authors:  S Al-Obeid; Q Haddad; A Cherkaoui; J Schrenzel; P François
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

8.  Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.

Authors:  R K C Fong; J Low; T H Koh; A Kurup
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-22       Impact factor: 3.267

Review 9.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 10.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.